within Pharmacolibrary.Drugs.ATC.A;

model A10BX02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.62,
    Cl             = 0.6333333333333333,
    adminDuration  = 600,
    adminMass      = 0.002,
    adminCount     = 1,
    Vd             = 0.031,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02666666666666667,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Repaglinide is an oral antihyperglycemic agent of the meglitinide class used to manage type 2 diabetes mellitus by stimulating insulin secretion from the pancreas. It is approved and widely used today for glycemic control in adults with type 2 diabetes.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers, single-dose administration, both sexes, age 18-60.</p><h4>References</h4><ol><li><a href='https://dx.doi.org/10.1007/s002280100404'>10.1007/s002280100404</a> All pharmacokinetic parameters were extracted from the reference by DÃ¼ring, et al., European Journal of Clinical Pharmacology (2000). ka was estimated from mean values in Table 2. Central and peripheral volumes are reported as Vc and Vp, respectively.</li></ol></body></html>",
    revisions = "<html><body><ul><li>03/06/2025 model generated from PK parameters and knowledge obtained by LLM gpt-4.1 and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10BX02;
